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Abstract
Variation in platelet response to thrombin may affect the safety and efficacy of PAR antagonism. 
The Thr120 variant of the common single nucleotide polymorphism (SNP) rs773902 in the 
protease-activated receptor (PAR) 4 gene is associated with higher platelet aggregation compared 
to the Ala120 variant. We investigated the relationship between the rs773902 SNP with major 
bleeding and ischemic events, safety, and efficacy of PAR1 inhibition in 6177 NSTE ACS patients 
in the TRACER trial. There was a lower rate of GUSTO moderate/severe bleeding in patients with 
the Thr120 variant. The difference was driven by a lower rate in the smaller homozygous group 
(recessive model, HR 0.13 [0.02–0.92] p=0.042). No significant differences were observed in the 
ischemic outcomes. The excess in bleeding observed with PAR1 inhibition was attenuated in 
patients with the Thr120 variant, but the interactions were not statistically significant. In summary, 
lower major bleeding rates were observed in the overall TRACER cohort with the hyperreactive 
PAR4 Thr120 variant. The increase in bleeding with vorapaxar was attenuated with the Thr120 
variant, but we could not demonstrate an interaction with PAR1 inhibition. These findings warrant 
further exploration, including those of African ancestry where the A allele (Thr120) frequency is 
~65%.
Keywords
platelets; PAR1; PAR4; bleeding; pharmacogenetics
1. Introduction
Patients with acute coronary syndromes are at risk of subsequent coronary events due to 
platelet thrombosis on a lipid-rich plaque [1, 2]. Antiplatelet therapies are critical to mitigate 
the risk of atherothrombotic events but at the same time increase the risk of bleeding [2–5]. 
Bleeding complications are associated with increased mortality, and decision of potency and 
duration of antiplatelet medications should be based on the assessment of the risk of 
thrombotic events vs. bleeding complications [6, 7]. There are well-established inter-
individual variations in platelet reactivity and platelet response to anti-platelet agents, and 
we have shown there is a substantial genetic component to both types of variations [8, 9] that 
may play a role in determining the risk of bleeding and coronary events [10–12]. Many of 
the challenges with platelet functional assays for assessing bleeding and thrombosis risk that 
can be overcome with nucleic acid-based assays [13]. Thus, identifying genetic biomarkers 
of variation in platelet reactivity may help with risk stratification of ischemia and bleeding 
and improve individual tailoring of antiplatelet medications [14–18].
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Thrombin is the most potent platelet activator, acting through the protease-activated 
receptors (PARs) [19]. The PAR1 receptor has classically been identified as the primary 
mediator of thrombin effects on human platelets since it is activated at a lower thrombin 
concentration [20]. However, PAR1 signaling is a rapid-on and rapid-off mechanism, 
whereas thrombin-induced PAR4 signaling has slower activation kinetics, but a sustained 
response. PAR4 has an overall greater contribution to platelet calcium flux than PAR1 [21, 
22]. We have previously reported that a single nucleotide dimorphism (G/A), rs773902 of 
the PAR4 gene (F2RL3) determines the Ala120 or Thr120 variants and that the Thr120 
variant was associated with higher PAR4 induced platelet aggregation in humans [23]. 
Notably, the allele frequency of rs773902 G or A varies by race, with the G allele more 
common in whites than blacks (~80% vs. 37%, respectively) and the A allele less common 
in whites than blacks (~20% vs. 63%, respectively) [24]. Another rare SNP, rs2227346 (only 
seen on the rs773902 A allele in blacks), results in a Phe296Val substitution and the Val 296 
variant markedly reduces PAR4 signaling [24]. An increased response to thrombin via PAR4 
could favor platelet-mediated hemostasis and thrombosis events, but it is unknown whether 
either PAR4 variant modifies the risk of bleeding or ischemic events in vivo. In addition, 
under conditions where PAR1 is nearly fully inhibited, such as with the use of the potent 
PAR1 antagonist vorapaxar, the residual response of platelets to thrombin is due to PAR4 
activation [25]. Therefore, inter-individual variation in platelet PAR4 reactivity could also 
influence bleeding and thrombotic events in patients treated with PAR1 antagonists, and 
especially bleeding when two different platelet signaling pathways are inhibited by aspirin 
or P2Y12 blockade.
Using the platform of the TRACER trial of vorapaxar vs. placebo in patients with non-ST-
segment elevation acute coronary syndromes (NSTE ACS) and the DNA samples collected 
as part of the trial biorepository, we genotyped participants for the rs773902 and rs2227346 
SNPs [26]. The overarching hypothesis of our analysis was that genetically determined 
variability in PAR4 function would influence the risk of bleeding and thrombotic events 
among patients who were treated with vorapaxar. In particular, our goals were to test 
whether rs773902 G or A could mitigate the increased risk of major bleeding observed with 
vorapaxar and to assess the effect of PAR4 genetic variability in patients following NSTE 
ACS.
2. Materials and methods
2.1. The TRACER trial
The design and results of the TRACER trial have been reported [26]. In brief, the TRACER 
trial included 12,944 patients with NSTE ACS and high-risk features within 24h of hospital 
presentation. Patients were randomized to vorapaxar 40 mg loading dose and 2.5 daily 
maintenance dose or matching placebo. Patients had to be treated for a minimum of one year 
and for the entire duration of the study, which was an event-driven trial. The trial was halted 
5 months prior to its planned conclusion after a Data Safety Monitoring Board review, which 
reported an increased risk of intracranial hemorrhage after the enrollment was completed 
and the minimum number of endpoint events had been reached (median follow up 502 days). 
In TRACER vorapaxar was associated with a non-significant reduction of the primary 
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endpoint, a composite of death from cardiovascular causes, myocardial infarction, stroke, 
recurrent ischemia with rehospitalization, or urgent coronary revascularization and a 
nominally significant reduction in death from cardiovascular causes, myocardial infarction, 
stroke. Vorapaxar significantly increased GUSTO moderate or severe bleeding and 
intracranial hemorrhage.
A TRACER trial biorepository was created which included blood samples for genetic and 
biomarker analysis. A total of 7,927 consented to the supplemental collection of the genetic 
sample (blood for DNA and RNA analysis).
2.2. Genotyping
Blood samples from patients who consented to voluntary participation in the genetic 
substudy were collected in DNA PAXgene tubes (PreAnalytiX, Hombrechtikon, 
Switzerland) for DNA analysis. Because the additional collection of DNA samples was 
voluntary and subject to individual country regulations, about 60% of the trial cohort had 
available DNA for genetic analysis. Samples were genotyped for rs773902 and rs222736 
using TaqMan SNP Genotyping Assays (Life Technologies Carlsbad, CA) as previously 
described [24]. Control DNAs for each allele (that had been sequenced) were included on 
each plate.
2.3. Statistical Analysis
Based on the prior platelet function studies, we hypothesized that patients with at least one 
copy of the hyperreactive rs773902 A allele had a decreased rate of major bleeding. We also 
hypothesized that bleeding liability with the PAR1 antagonist vorapaxar would be lower in 
presence of the A allele, as the increased PAR4 function would provide a more effective 
pathway for thrombin-mediated platelet activation through the PAR4. Finally, we 
hypothesized that patients with at least one copy of the rs773902 A allele would have 
increased risk of ischemic events and reduced efficacy from vorapaxar. For this analysis 
patients were classified in 3 groups: F2RL3 rs773902 AA homozygous (Thr/Thr120); AG 
heterozygous (Thr/Ala120), GG homozygous (Ala/Ala120)
Similarly, we hypothesized that patients with at least one copy of the rs2227346 G allele 
(encodes Val296) are at increased risk of bleeding and relatively higher bleeding risk when 
treated with vorapaxar, compared with placebo.
The main bleeding outcomes for the study were non-CABG related GUSTO Moderate and 
Severe and intracranial hemorrhages. The main ischemic outcome was the composite of 
cardiovascular death, myocardial infarction or stroke. The event accrual period for the 
analysis was from hospital discharge to 24 months.
To describe the relationship between the rs773902 and clinical events and their timing, 
Kaplan-Meier (KM) rates stratified by genotype were computed for each endpoint and were 
compared across genotype using the log-rank test. The relationship between the F2RL3 
variant rs773902 genotype and clinical events was assessed by fitting a Cox proportional 
hazards model for the time-to-first event. The association is characterized by the genotype 
hazard ratio (HR) and the corresponding 95% confidence interval (CI) and p-value. 
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TRACER used self-identified race and ethnicity (called “race”). To minimize population 
confounders, self-identified non-white patients were excluded in the primary analysis. This 
analysis was repeated modeling the rs773902 genotype under an additive, dominant, and 
recessive model.
To describe the relationship between rs773902 and rs227346 variants, vorapaxar and clinical 
event Kaplan-Meier rates were calculated by genotype overall and by treatment arm for each 
endpoint of interest. Event counts were compared across genotype using the log-rank test. 
To determine if the relationship between vorapaxar and clinical events differ by rs773902 
genotype, an interaction term between genotype and treatment arm was included in the 
model and tested. The relationship between treatment and outcome was characterized by the 
vorapaxar vs. placebo HR and the corresponding 95% CI within each genotype and by the 
interaction p-value.
3. Results
3.1. TRACER PAR4 Genetic Substudy participants
Of the 12944 patients included in the TRACER trial 7927 individual agreed to participate in 
the Genetic Substudy (Figure 1). Among these, sufficient material for DNA analysis was 
collected in 6890 subjects. 632 non-white patients were not included. For 81 patients it was 
not possible to match the sample ID to the main trial database (i.e., genetic data are de-
identified and not kept into the main trial database). The final sample size for this PAR4 
Genetic Study analysis included 6177 patients, and the baseline characteristics are shown in 
Table 1. The PAR4 Genetic Study is representative of the entire TRACER study except for 
the limitation to white subjects in the PAR4 Genetic Study; the demographic variables are 
similar across all genotypes.
3.2. F2RL3 Genotypes
The rs773902 SNP was successfully genotyped in 99.5% of samples; 31 could not be 
definitively assigned a genotype. The rs773902 genotypes for the entire cohort showed that 
3884 (63.2%) patients were G/G genotype, 1995 (32.4%) were A/G and 267 (4.3%) were 
A/A genotype. The rare rs2227346 G allele was present in 15 patients (0.2%), all of whom 
were heterozygous G/T; no homozygous G/G subjects were present in our cohort. Given the 
small number of patients with the rare rs2227346 G allele, we did not test for associations of 
this allele with further event rates or interaction with vorapaxar.
3.3. F2RL3 Genotypes and Bleeding Outcomes
In the PAR4 Genetic Study, there was a lower rate of GUSTO moderate or severe bleeding 
with the presence of the A allele (p=0.053) (Table 2). As shown in Table 3, the association 
between bleeding and genotype was not statistically significant using the additive genetic 
model (HR 0.84, 95% CI 0.64 – 1.11) or dominant genetic model (HR 0.93, 95%CI 0.68–
1.28). The recessive genetic model showed a significant reduction in the risk of bleeding 
associated with the allele A (HR 0.13, 95%CI 0.02–0.92), suggesting a bleeding risk 
reduction with the presence of 2 copies of the hyperactive A allele.
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In our analysis cohort, only 22 intracranial hemorrhages were observed by 24 months post-
discharge. None of the ICH as observed in the homozygous AA group, while the rate of ICH 
was 0.4% in the AG and 0.8% in the GG group.
3.4. F2RL3 Genotypes and Ischemic Outcomes
There were no significant differences in the occurrence of cardiovascular death, myocardial 
infarction or stroke according to the F2RL3 genotypes (Table 2). Numerical imbalances 
observed were contrary to the study hypothesis, with lower rates in the AA group. The 
additive, dominant and recessive models were all non-significant (Table 3).
3.5. Vorapaxar Effect on Bleeding by F2RL3 Genotypes
We next estimated the treatment difference among genotypes. The relative increase in 
GUSTO moderate or severe bleeding observed with vorapaxar was higher in the GG group, 
known to have lower platelet PAR4 reactivity (Table 4). Because the number of bleeding 
events was too small to perform a recessive model analysis, we considered patients with at 
least one copy of the A allele (i.e., a dominant model). As shown in Table 5, the Hazard 
Ratio of bleeding with vorapaxar in this group was 1.06 (95% CI 0.64 – 1.78), while in the 
GG group the HR was 1.45 (95% CI 0.99 – 2.13). The interaction term was not statistically 
significant.
The number of intracranial hemorrhages was overall low. There were no intracranial 
hemorrhages in patients with AA genotypes. In patients with AG genotypes, there was a 
doubled rate of intracranial hemorrhage with vorapaxar v. placebo (0.3% vs. 0.6%). In 
patients in the GG group there we observed a 7-fold increase in the occurrence of 
intracranial hemorrhage with vorapaxar compared to placebo (1.4% vs. 0.2%). In the 
dominant model, among patients with at least one copy of the A allele, the Hazard Ration of 
intracranial hemorrhage with vorapaxar was 1.50 (95% CI 0.25 – 8.98), while in the GG 
group the HR was 2.69 (95% CI 0.71– 10.13).
3.6. Vorapaxar Effect on Ischemic Outcomes by F2RL3 Genotypes
A reduction in cardiovascular death, myocardial infarction or stroke with vorapaxar was 
observed in all groups (Table 2), but there was no significant interaction between genotypes 
and treatment using the additive, dominant or recessive models.
4. Discussion
Inhibition of the PAR1 thrombin receptor provides benefit in the secondary prevention of 
ACSs in some settings, but its use has been limited due to concerns of major bleeding. The 
rationale for the current study was to identify a genetic predictor that could identify patients 
with a lower bleeding risk in the setting of anti-platelet therapies. To our knowledge this is 
the first study testing for associations between a common thrombin receptor polymorphism 
and clinical outcomes in a large, randomized clinic trial of patients with NSTE ACS [26]. 
Although thrombin receptors have a broad tissue distribution, our hypotheses were based on 
abundant in vitro data using human blood that demonstrated enhanced platelet activation and 
aggregation from healthy individuals expressing the rs773902 A allele encoding Thr in the 
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PAR4 thrombin receptor [23, 24, 27]. The most important finding from our work was that 
the rs773902 AA genotype conferred a significant reduction in GUSTO moderate or severe 
bleeding. Our findings may have implications for the future development of PAR inhibitors 
generally, and for PAR4 inhibitors specifically [28, 29].
The major physiologic role for platelets is to maintain hemostasis, and thrombocytopenia 
and platelet dysfunction are well-established risks for bleeding. Anti-platelet therapy with 
aspirin and P2Y12 inhibition block secondary feedback pathways of platelet activation and 
have become standards of care for secondary prevention of ACSs. The development of 
effective anti-platelet agents that inhibit a third, though primary, activation pathway has the 
difficult challenge of demonstrating clinical benefit in the face of likely enhanced bleeding 
with triple anti-platelet therapy. Indeed, this challenge has appeared to be the case with 
vorapaxar, which inhibits the PAR1 thrombin receptor. Our analyses showed that patients 
homozygous for the rs773902 A allele had less GUSTO severe/moderate bleeding, which is 
consistent with a mechanism whereby the hyperactive Thr120 PAR4 isoform promotes 
normal hemostasis. Smaller numbers of patients met the criteria for TIMI major or minor 
bleeding, but trends in the same direction were observed (not shown). While we could not 
demonstrate an interaction between vorapaxar use and rs773902, a significant increase in 
bleeding was observed in the GG group only. And since most patients in TRACER were 
using both aspirin and a P2Y12 inhibitor, the enhanced hemostasis with the A allele is also 
consistent with in vitro studies showing platelets from donors expressing the rs773902 A 
allele are less sensitive to the inhibitory effects of both aspirin and P2Y12 inhibition [27]. 
Notably, our modeling of the effect of the A alleles showed a significant reduction in 
bleeding in the whole population only with the recessive model, suggesting that two copies 
of the A allele may be required to significantly modify the bleeding tendency in TRACER. 
The additive and dominant model showed a directionally consistent result but were not 
statistically significant. The Thr for Ala substitution at residue 120 in the 2nd transmembrane 
domain of PAR4 changes a nonpolar residue to a polar residue, which could favor PAR4 
homodimerization [30] and enhanced signaling in the homozygous state.
We did not observe an association between rs773902 A and ischemic events. This 
observation was not entirely unexpected since, unlike hemostasis where platelets play a 
central and critical role, atherothrombosis is a complex and multifactorial disease, involving 
other pathophysiologic mechanisms such as elevated blood pressure, altered glucose or lipid 
metabolism, endothelial dysfunction, etc. Our hypotheses were based on in vitro platelet 
studies, but PARs have other platelet-independent functions, and are involved in response to 
injury and inflammation and their proteases may signal differently in other cells. There are 
no data on the functional effect of the PAR4 variant in non-platelet tissues [31, 32], and 
perhaps the lack of an association of rs773902 with ischemic outcomes in TRACER is 
related to unknown effects of the PAR4 variants to the vasculature [33, 34]. Moreover, 
atherothrombosis is a complex and multifactorial disease and not determined by single gene, 
therefore a single genetic variant may have a relatively minor effect on the onset and 
progression of the disease.
This study had several limitations. First, this was a selected cohort of patients randomized in 
a clinical trial after suffering an NSTE ACS. Because patients during the acute period were 
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treated with multiple antithrombotic therapies and had undergone invasive procedures, we 
decided to start the accrual period for the analyses at the time of discharge from the index 
hospitalization. While this selection was arbitrary, it is a standard time point for post-ACS 
studies, and we believe that this selection allowed an adequate assessment of the effect of the 
genotypes in our cohort. Finally, the prevalence of homozygous AA in our cohort was small, 
accounting for slightly over 4% of the populations. This low prevalence means that, if in 
fact, a significant effect on bleeding requires homozygous status, our study may have been 
underpowered. At the same time, although biologically plausible and in line with the study 
hypothesis, a chance finding is also possible given the small group size.
The findings of this analysis are limited to an NSTE ACS cohort of patients who were 
discharged from an acute event. Despite these limitations, our analysis is the first assessment 
in a large cohort of the association between PAR4 genotypes and bleeding and the potential 
impact of PAR4 genotypes on safety and efficacy of concomitant PAR1 inhibition.
We conclude that the SNP rs7773902 of PAR4 gene may influence the bleeding risk and 
bleeding liability with vorapaxar after an NSTE ACS, especially in allele A homozygotes. 
Further studies are needed to confirm this finding. Our findings may be of particular 
relevance for patients of African descent ~40% of whom are homozygous AA for 
rs7773902, while the TRACER population only included 2.5% of African American [24]. In 
data not shown, when blacks were included in our analyses, none of the results materially 
changed, with only a minimal change in the rate of GUSTO moderate or severe bleeding 
with the presence of the A allele (p=0.035). Our study should serve as basis for future 
studies that include sufficient numbers of African Americans or patients with other 
cardiovascular conditions, such as those with chronic stable disease. It will also be important 
to consider PAR4 functional variants in those on-going trials of PAR4 antagonists in 
platelet-mediated cardiovascular diseases [28, 29] or other conditions where PAR4 or race 
may play a pathophysiologic role.
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Figure 1. 
Consort Diagram
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